Molecular Imaging in the Treatment of Kaposi's Sarcoma
Molecular Imaging in the Treatment of Kaposi's Sarcoma
批准号:
8566681
负责人:
RICHARD Frederick AMBINDER
金额:
$17.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2016-07-31
关键词:
BiometryBortezomibClinicalCollectionDevelopmentEnsureEnvironmentEnzymesEquipmentExtracellular MatrixFive-Year PlansFundingFutureGoalsImageImaging technologyKaposi SarcomaLungMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMetastatic Neoplasm to the BoneMetastatic Prostate CancerModalityMolecularNeoplasm MetastasisOncologistPathologistPathway interactionsPatientsPositron-Emission TomographyRadiationRenal carcinomaResearchResearch InfrastructureResearch PersonnelResourcesScientistStructureSurgeonTranslatingTranslationsTreatment EfficacyTreatment outcomebasebench to bedsidecareer developmenteffective therapyepithelial to mesenchymal transitionhypoxia inducible factor 1imaging modalityimaging probeimprovedin vivo Cellular and Molecular Imaging Centersmelanomamolecular imagingmolecular oncologyoncologyoptical imagingprogramsradiologistsingle photon emission computed tomographytheranosticstumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
For our next five-year plan we have aligned ourselves to the goals of discovering, developing, and
translating molecular imaging technologies to understand, detect, and treat cancer. Our efforts and
expertise will be applied collectively and synergistically for this purpose. By engaging and integrating
clinical oncologists, radiologists, pathologists, and surgeons within every aspect of the program, we have
ensured the translation of our most exciting discoveries to improve treatment outcome in patients. This
unique collection of highly interactive research-scientists and clinician-scientists within an environment rich
in multi-modality imaging expertise and equipment is necessary to make the catapulting advances and
discoveries that are essential to find effective treatments for cancer. The JHU ICMIC Program consists of
four research components, four developmental projects, four resources, and a career development
component. The four research components have a major emphasis on clinical translation and cover
different aspects of understanding, detecting, and treating cancer. These are (i) theranostic imaging of
metastatic prostate cancer, (ii) BETR (bortezomib-induced enzyme targeted radiation) theranostics for
Kaposi's sarcoma (KS), (iii) exchange transfer-based molecular MRI in oncology and (iv) molecular
imaging of the extracellular matrix (ECM) and its avenues for metastasis. Similarly, the four developmental
projects cover a range of topics, such as (i) force propagation in melanoma cancer progression, (ii) imaging
peri-tumoral stromal depletion as a surrogate for treatment efficacy in pancreatic cancer, (iii) lung-specific
Twist mediated epithelial to mesenchymal transition (EMT) in lung premetastatic niche, and (iv) blockade of
the hypoxia inducible factor (HIF)-1 pathway in bone metastasis from renal cancer. We have structured
four specialized resources (the Administrative Resource, the Molecular Oncology Resource, the Imaging
and Probes Resource, and the Biostatistics Resource) to provide the infrastructure to support the current
and future projects of the JHU ICMIC. The Career Development Component is structured with the purpose
of creating independently funded investigators who will, in the future, become leaders in the field.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating the EBV methylome in PLWH: Discovery and Development of Novel EBV Diagnostics in Plasma and Saliva
-
批准号:10755171
-
项目类别:
-
资助金额:$71.37万
-
财政年份:2023
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Clonal Immunoglobulin DNA and Lymphoma Diagnosis
-
批准号:9927306
-
项目类别:
-
资助金额:$17.51万
-
财政年份:2020
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
-
批准号:10377440
-
项目类别:
-
资助金额:$81.44万
-
财政年份:2020
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
-
批准号:10824451
-
项目类别:
-
资助金额:$10.44万
-
财政年份:2020
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
-
批准号:10681861
-
项目类别:
-
资助金额:$10.44万
-
财政年份:2020
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
-
批准号:10613422
-
项目类别:
-
资助金额:$84.93万
-
财政年份:2020
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Plasma and serum biomarkers for Hodgkin lymphoma
-
批准号:8913087
-
项目类别:
-
资助金额:$17.84万
-
财政年份:2014
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Plasma and serum biomarkers for Hodgkin lymphoma
-
批准号:8771661
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2014
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
BETR Therapy for Herpesvirus-Associated Tumors
-
批准号:8233508
-
项目类别:
-
资助金额:$55.03万
-
财政年份:2010
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
BETR Therapy for Herpesvirus-Associated Tumors
-
批准号:8447549
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
BETR Therapy for Herpesvirus-Associated Tumors
-
批准号:8644784
-
项目类别:
-
资助金额:$52.07万
-
财政年份:2010
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
BETR Therapy for Herpesvirus-Associated Tumors
-
批准号:7784032
-
项目类别:
-
资助金额:$58.24万
-
财政年份:2010
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
BETR Therapy for Herpesvirus-Associated Tumors
-
批准号:8043619
-
项目类别:
-
资助金额:$55.35万
-
财政年份:2010
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Network Laboratory
-
批准号:7130680
-
项目类别:
-
资助金额:$14.83万
-
财政年份:2006
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
VACCINATION OF PATIENTS AT RISK FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
-
批准号:7604557
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2006
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
VACCINATION OF PATIENTS AT RISK FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
-
批准号:7200735
-
项目类别:
-
资助金额:$0.65万
-
财政年份:2005
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
VACCINATION OF PATIENTS AT RISK FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
-
批准号:7378818
-
项目类别:
-
资助金额:$0.48万
-
财政年份:2005
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Vaccination of Patients at Risk for Post-Transplant Lymphoproliferative Disorder
-
批准号:7044685
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2003
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
Adult Hodgkin's Disease and Epstein Barr Virus
-
批准号:6623404
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2002
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
SPORE in Lymphoma
-
批准号:6917225
-
项目类别:
-
资助金额:$254.5万
-
财政年份:2002
-
负责人:RICHARD Frederick AMBINDER
-
依托单位:
国内基金
海外基金
bortezomib抑制寨卡病毒复制的分子机制研究
-
批准号:82272328
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:石磊
-
依托单位:
蛋白酶体抑制剂硼替佐米(Bortezomib)对血管渗漏的改善及机制研究
-
批准号:81772041
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2017
-
负责人:汤耀卿
-
依托单位:
蛋白酶体抑制剂Bortezomib对肺动脉平滑肌细胞钙离子通路的作用研究
-
批准号:81460011
-
项目类别:地区科学基金项目
-
资助金额:40.0万元
-
批准年份:2014
-
负责人:徐磊
-
依托单位: